STAREE just filled a real evidence gap — and it’s not a simple “everyone over 70 should start a statin” story. STAREE randomized 9,971 community-dwelling adults 70+ with no history of heart disease, diabetes, or dementia to atorvastatin 40 mg or placebo. Median follow-up was 5.9 years. Mean age was about 75; just over half were women. It was publicly funded and run through Australian primary care. What it found Major CV events (CV death, nonfatal MI, stroke, or coronary revascularization): 6.0% vs 8.3% — a 30% relative reduction (HR 0.70). Absolute risk reduction: about 2.3% over ~6 years. NNT ≈ 37 over that period. The benefit was driven mainly by fewer heart attacks and fewer revascularizations. Disability-free survival (alive without dementia or persistent physical disability) did not improve (HR ~0.94, not significant). All-cause death did not clearly fall. Dementia did not increase. Serious adverse events were similar. Muscle, liver, and diabetes-related events were modestly more common on atorvastatin. How doctors are reading it One camp says age alone should no longer be a reason to withhold a statin in a healthy 70-year-old who wants to prevent a first heart attack. .The trial finally tested that question directly. The other camp says the headline 30% is relative. The absolute gain is small, there is no extra healthy lifespan, and many older people care more about independence than about a nonfatal event. John Mandrola called it a conversation starter, not a mandate. Adam Cifu said it would change his practice only a little. Critics also note the NNT looks less impressive when framed per year, and that the trial population was relatively healthy and almost entirely White. Both readings can be true at once. Pros of the trial First large primary-prevention statin RCT built for people 70+. Independent funding. Dual primary endpoints that include what older patients often value: staying independent. Benefit seen in those 75+ as well. No signal for more dementia. Serious harm rates were not higher. The useful takeaway STAREE does not settle “statins for every healthy 75-year-old.” It does settle this: if an independent older adult without known CVD wants to lower the chance of a first heart attack or needing a procedure, atorvastatin has randomized evidence behind it. If their priority is living longer without disability, this trial did not show that. That’s a values conversation with a clinician — life expectancy, frailty, other meds, LDL, blood pressure, and what the person actually fears — not a default yes or no. Sources: NEJM / ESC 2026 STAREE #STAREE #ESC2026 #ESCCongress #Cardiology #PreventiveCardiology #PrimaryPrevention #Statins #Atorvastatin #GeriatricCardiology #Lipids #ASCVD #MedTwitter #CardioTwitter #FOAMed #InternalMedicine #FamilyMedicine #Geriatrics #EvidenceBasedMedicine #SharedDecisionMaking #NEJM